BACKGROUND Small-cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis and marked transcriptional heterogeneity that may drive distinct therapeutic vulnerabilities. Clinical translation of molecular subtyping has been limited by restricted access to tumor biopsies, particularly at relapse. METHODS W...
Gavriel Fialkoff, N. Takahashi, Israa Sharkia et al.· Journal of Clinical Investig...· 0 citations
This represents one of the first spatially resolved analyses of TLS-like immune architecture in SCLC, demonstrating that organized lymphoid immunity can emerge in this classically immune-evasive disease and is associated with improved survival.
Yingying Cao, M. Nirula, Paul Mallory et al.· bioRxiv· 0 citations
An integrated proteogenomic pipeline combining single-cell RNA sequencing, combinatorial optimization, mass spectrometry–based proteomics, and immunohistochemistry is developed to systematically map the SCLC surfaceome of 49 tumors across 25 patients with relapsed SCLC and found claudin-3 (CLDN3) to be a consistently e...
Brett Schroeder, Jaehyun Choi, Alejandro A. Schäffer et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.